Vita Life Sciences

Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges

Robbo

Not Invested

Community Contributor

Published

02 Jun 25

Robbo's Fair Value

AU$2.42

4.1% overvalued

05 Jun

AU$2.52

9.6%

1.6%

9.6%

1.6%

You can edit this narrative until Jun 2 2:30 AM. Then, changes will post as Updates.

Author's Valuation

AU$2.4

4.1% overvalued

Robbo's Fair Value

Narrative

Updates0

Robbo'sFair Value

AU$2.42

4.1% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.00%

Pharma revenue growth rate

0.61%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$15.98m

Earnings '30

11.43x

PE Ratio '30

AU$182.75m

Market Cap '30

AU$182.75m

Market Cap '30

56.74m

No. shares '30

AU$3.22

Share Price '30

AU$3.22 Share Price '30

Discounted to 2025 @ 6.41% p.a.

AU$2.36

Fair Value '25